Search Results

<< Go Back to NCF Events Page No registration required. HOW TO JOIN THE VIRTUAL LUNCHEON Submit your general questions for the Live Q&A on YouTube OR Facebook via chat. “ Luncheon With The Experts ” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — who present on topics relevant to neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live ) at noon Eastern Time, allowing participants to join with their lunch break. Live sessions are recorded and will be available afterwards. ABOUT DR. BORIS G. NARAEV, MD, PHD, FACP Dr. Naraev is a board-certified medical oncologist at the Tampa General Hospital’s Cancer Institute specializing in caring for people living with neuroendocrine and endocrine tumors. He is an Associate Professor of Medicine at the Division of Hematology and Medical Oncology of University of South Florida, Morsani College of Medicine. Prior to joining the TGH Cancer Institute, he was the Lead of Neuroendocrine Cancer Program at Banner MD Anderson Cancer Center in Phoenix, Arizona and Adjunct Assistant Professor with the Department of Gastrointestinal Medical Oncology at The University of Texas MD Anderson Cancer Center, Houston, Texas. While in Phoenix, he helped create, develop, and lead one of the largest neuroendocrine cancer programs in the Southwestern United States, and was personally taking care of a large population of patients with neuroendocrine tumors. Later, he served as the Leader of Gastrointestinal, Neuroendocrine, and Rare Cancers Program at the Anderson Family Cancer Institute at Jupiter Medical Center in Jupiter, Florida. In this capacity, he helped build the National Pancreas Foundation Pancreatic Cancer Center of Excellence at Jupiter Medical Center. He received his Doctor of Medicine degree from Orenburg State Medical Academy in Orenburg, Russia. Subsequently, he obtained a PhD in Medical Sciences degree from the same institution. After completion of Internal Medicine residency training at St. Luke's Hospital in Chesterfield, Missouri, he proceeded to complete Hematology/Oncology Fellowship at the University of Iowa Hospitals and Clinics in Iowa City, Iowa. During his fellowship training, he developed a special interest in neuroendocrine tumors and completed several research projects in this field. Dr. Naraev is involved in neuroendocrine tumors related research and community outreach, and is a member of the NETPact Committee and Chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS). Dr. Naraev also serves as a member of the National Cancer Institute’s Neuroendocrine Tumors Task Force. HOST The sessions are hosted by Rain Bennett , a two-time Emmy-nominated filmmaker, author, and experienced host who produces and leads live conversations on behalf of the Neuroendocrine Cancer Foundation. Bennett has been involved with the neuroendocrine cancer community as a longtime filmmaker and supporter, using his storytelling and interview skills to bring expert perspectives to patients and caregivers. THANKS TO OUR SPONSORS The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. << Go Back to NCF Events Page

Clinical Trials Guide What’s Going On With Clinical Trials By type of disease or treatment Browse by Trial How to Use Our Clinical Trials Guide Ancora.ai Clinical Trial Finder What’s Going On With Clinical Trials Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Interviews With Experts By type of disease or treatment Browse Clinical Trials by Type of Disease or Treatment: Pheochromocytoma/ Paraganglioma Click Here Gastrointestinal (GI) NETs Click Here NIH/NCI Natural History Study for Neuroendocrine Neoplasms Click Here Immunotherapy Click Here PRRT/Radioligand Therapy (RLT) Click Here Targeted Therapies Click Here Lung/Bronchial NETs Click Here Pancreatic NET (PNET) Click Here Carcinoid Syndrome Click Here G3 Neuroendocrine Neoplasms (NEN) or High Grade Click Here Additional Resources Click Here Other Click Here IN-DEPTH LOOK: CLINICAL TRIALS Research / Clinical Trials Play Video Play Video 14:15 Tarlatamab in DLL3-Expressing Tumors Including NEN • ClinicalTrials.gov: NCT06788938 • Dr. Goldman Join Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this talk, Dr. Goldman explains: - What DLL3 is and why it is an important target found on many neuroendocrine tumors - How tarlatumab works by connecting T-cells to tumor cells to trigger a focused immune response - Why DLL3-positive tumors—including small cell lung cancer, lung carcinoids, thymic tumors, pancreatic NETs, gastrointestinal NETs, prostate NEC, Merkel cell carcinoma, and others—may respond to this therapy - The structure of the L10 Clinical Trial, now in Stage 2 and enrolling across all University of California cancer centers - What patients can expect from the tarlatumab treatment schedule and dosing - Potential side effects such as cytokine release syndrome, fatigue, constipation, loss of taste, neurologic symptoms, and tumor lysis syndrome Dr. Goldman highlights both the promise of DLL3-targeted therapies and the ongoing need to understand how DLL3 expression levels relate to patient response. For more information, visit https://www.ncf.net/clinical-trials-1/tarlatamab Play Video Play Video 13:57 A Study of ZL-1310 in Participants With Selected Solid Tumors • ClinicalTrials.gov ID: NCT06885281 Dr. Rohit Thummalapalli discusses "A Study of ZL-1310 in Participants With Selected Solid Tumors" (ClinicalTrials.gov ID: NCT06885281). For more information, visit NCF.net/clinical-trials Play Video Play Video 06:54 (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen•NCT07087054 Dr. Aman Chauhan discusses (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (ClinicalTrials.gov: NCT07087054). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 08:57 Study of 225Ac-ABD147 to Establish Optimal Dose • ClinicalTrials.gov: NCT06736418 • Dr. Chauhan Dr. Aman Chauhan discusses the Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy (ClinicalTrials.gov: NCT06736418). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 08:57 (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET • ClinicalTrials.gov ID: NCT06943755 Dr. Aman Chauhan discusses (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors. Visit https://www.ncf.net/clinical-trials for more information. Play Video Play Video 12:34 May 19, 2025: Dr. Aman Chauhan discusses the DAREON-5 & DAREON-7 Studies DAREON-5 is a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. This is a clinical trial for high grade neuroendocrine cancers. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. The study is sponsored by Boehringer Ingelheim. For more information, visit https://www.lacnets.org/clinical-trials-1/dareontm--5%3A-dll-3-bite-for-neuroendocrine-cancers. Play Video Play Video 16:57 SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated NEC or Well-Differentiated High-Grade NET Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors. Recorded: April 22, 2025 For more information, visit https://www.ncf.net/clinical-trials-1/svv-001 Play Video Play Video 29:35 IL13Rα2 CAR T Cell Study for Solid Tumor Cancers • Dr. Anusha Kalbasi Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024. For more information about this trial, visit https://www.lacnets.org/clinical-trials-1/il13r%CE%B12-car-t-cell-study-for-solid-tumor-cancers. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Browse by Trial: 225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Belzutifan-MK-6482 in PNET + PPGL + VHL BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen CDK4/6 Abemaciclib GEP-NETS CHM-2101 CAR-T cell for GI Cancers ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib in NETs Lu-177 DOTATATE vs Everolimus in Lung NETs Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs Lu-177 DOTATATE + Olaparib in GEP-NETs Lu-177 DOTATATE + Sunitinib in PNETs Lu-177 DOTATATE + Triapine in GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) NET RETREAT: Retreatment with 177Lu-DOTATATE vs Everolimus in Metastatic Midgut NET NETTER-P: Lutathera in Adolescent Patients (12-17) with GEP-NETs and PPGLs Olaparib + Usual Chemotherapy (Temozolomide) in PPGL Paltusotine in Carcinoid Syndrome RYZ401: Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTR SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) SWOG S2104: Adjuvant CAPTEM for High Risk pNET SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism ZL-1310 in Participants With Selected Solid Tumors Browse by Trial UNDERSTANDING CLINICAL TRIALS Finding and learning more about relevant neuroendocrine cancer clinical trials may feel overwhelming. While comprehensive databases are available to search for trials, it may be difficult to understand whether a trial is right for you. Our goal is to offer a resource with key, open clinical trials for those with neuroendocrine cancer (aka, neuroendocrine neoplasm or NEN, including neuroendocrine tumor or NET and neuroendocrine carcinoma or NEC). We hope this information will help you better understand clinical trials and empower you to discuss them with your medical team. You may browse the Clinical Trials Guide in the following ways: Browse by selecting a type of disease or treatment. For example, if you are interested in open trials for pancreatic neuroendocrine tumor (PNET), click on the “PNET” image below. If you are interested in exploring peptide receptor radionuclide therapy (PRRT) trials, click on the “PRRT” image below. Browse by the trial using the table of contents. Click on individual trials to learn more information. Use the Ancora.ai clinical trial finder by entering your location and specifics about your tumor to find appropriate clinical trials. Then, browse this clinical trial guide to learn more about the suggested trials. When exploring the Clinical Trials Guide, you will find a description of each trial and contact information. Many also include a video of a NET expert describing the trial. The videos explain the study and who is eligible to participate. You can consider clinical trials at any time during your NET journey. Options range from first-line treatments for those newly diagnosed to novel treatments for those who have already had multiple treatments. For more information on how your involvement may benefit you and the NET community, read Why Participate in Clinical Trials . Download "Glossary of Common Terms in Clinical Trials" >>> Download "Clinical Trials: How to Prepare" >>> How to Use Our Clinical Trials Guide Ancora.ai Clinical Trial Finder Ancora.ai Ancora.ai is a neuroendocrine tumor clinical trial finder for patients and physicians developed by Ancora.ai and NorCalCarciNET. Ancora allows you to do a personalized search, filter and export results, and if interested, Ancora's patient team can help connect you to a trial site to begin the evaluation process. It's free and easy to use. Click here to access Ancora.ai >> DISCLAIMER: This information is for educational purposes only. The Neuroendocrine Cancer Foundation encourages you to discuss your individual care and treatment options with your medical team. The Neuroendocrine Cancer Foundation does not endorse any particular trial or treatment. This is not a complete list of available NET trials nor is it intended to be. For comprehensive information about available clinical trials, go to ClinicalTrials.Gov.

The Neuroendocrine Cancer Foundation Podcast (previously known as the LACNETS Podcast) is a monthly series where we interview neuroendocrine tumor (NET) experts on various NET topics. Each expert will answer the top 10 FAQs in their area of expertise. Whether a listener is newly diagnosed, a longtime NET survivor, or a family member or loved one, the Neuroendocrine Cancer Foundation Podcast serves as a tool to help anyone better understand NET. The Neuroendocrine Cancer Foundation Podcast is also available on Apple Music, Spotify, Google Podcasts, and Amazon Music. Be sure to subscribe to our podcast to receive notifications when new episodes are released! 2025 2024 2023 2022 2021 2025 2025 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2024 2024 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2023 2023 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2022 2022 LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN LISTEN 2021 2021 LISTEN LISTEN LISTEN LISTEN LISTEN

<< Go back to the Podcast page EPISODE 47: SPOTLIGHT ON ENDOCRINOLOGY Download a Transcript of this Episode >>> ABOUT THIS EPISODE Every provider on a multidisciplinary neuroendocrine cancer (NET) team brings a distinct and valuable perspective. In this episode, UCLA endocrinologist Dr. Run Yu sheds light on the unique role of the endocrinologist. He explains what endocrinology is, which types of NETs may require an endocrinologist's care, and how endocrine issues intersect with NET management. Dr. Yu also explores the “endocrine” side of neuroendocrine—discussing key concerns related to diabetes, thyroid, parathyroid, and adrenals. MEET DR. RUN YU Run Yu, MD, PhD, received his MD degree from Peking Union Medical College in Beijing and his PhD degree in pharmacology from University of Rochester in New York. Dr. Yu completed an endocrine research fellowship, an internal medicine residency, and a clinical endocrinology fellowship at Cedars-Sinai Medical Center. Dr. Yu’s clinical and research interests include diabetes, thyroid, and endocrine tumors and syndromes. Dr. Yu enjoys describing novel clinical findings in endocrinology. TOP TEN QUESTIONS: What is an endocrinologist? What training is involved? Since there is “endocrine” in neuroendocrine, would NET patients need to see an endocrinologist? When should one see an endocrinologist? What is your role with your medical team? How is an endocrinologist different from a medical oncologist? If someone with neuroendocrine cancer needs to see an endocrinologist, does that person need to specialize in neuroendocrine cancer? 3. If someone sees both an endocrinologist and a medical oncologist, what do you do and what does the medical oncologist do? How are treatment decisions made or coordinated? (Who is the “quarterback?”) 4. Who orders the somatostatin injections? Are they done through the oncologist or endocrinologist? What if I need something else to control my neuroendocrine cancer symptoms? 5. What are hormonal issues? How do I know if my neuroendocrine tumor produces hormones? 6. What hormone tests do you check? 7. What tumor markers do you check? How do you interpret them? 8. When might endocrine issues arise with neuroendocrine cancer? Thyroid Parathyroid Adrenal 9. How do hyperglycemia and diabetes issues relate to neuroendocrine cancer? What is hyperglycemia, pre-diabetes and diabetes? Is diabetes inevitable with NET? Is diabetes inevitable with somatostatin analogue therapy? Does metformin potentially slow down NET tumor growth? What monitoring do you recommend? 10. When does one encounter hypoglycemia with neuroendocrine cancer? What is insulinoma? What is the treatment? BONUS: What is on the horizon for neuroendocrine cancer that you’re most optimistic about? RESOURCES "The Endocrine in Neuroendocrine" • Run Yu, MD, Endocrinologist, UCLA • 2024 NET Cancer Day Symposium "Q&A with Experts" • Andrew Hendifar, MD, Run Yu, MD, & Jaydira Del Rivero, MD • 2024 NET Cancer Day DISCLAIMER The Neuroendocrine Cancer Foundation Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of the Neuroendocrine Cancer Foundation. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 11: PATHOLOGY FOR NETS Download a Transcript of this Episode >> ABOUT THIS EPISODE How do you understand your pathology report? What is tumor grade, differentiation, mitotic index, and ki67? How do you get a second opinion on your pathology? NET expert and pathologist Dr. Sue Chang of City of Hope answers ten common questions about pathology for neuroendocrine tumors. Dr. Chang defines important keywords to help you understand your pathology report which is instrumental in guiding treatment decisions. MEET DR. SUE CHANG Sue Chang, M.D., is an assistant clinical professor and interim chief of the Division of Anatomic Pathology in the Department of Pathology . Dr. Chang graduated cum laude from Harvard University in Cambridge, Massachusetts, and went on to receive her medical doctorate from New York Medical College in Valhalla, New York. Later, she completed an anatomical/clinical pathology residency at UCLA Health, where she was a chief resident and a resident informaticist. She furthered her training with a cytopathology fellowship at UCLA Health and a surgical pathology fellowship at Brigham and Women's Hospital in Boston. Board certified in anatomic pathology, clinical pathology, cytopathology and clinical informatics, Dr. Chang is the recipient of many honors and awards. She has published several articles in the peer reviewed literature, and has been invited to present her work nationally. Dr. Chang's professional interests include thyroid pathology and pathology informatics. She is active in the College of American Pathologists, currently serving as the chair for the Professional and Community Engagement Committee. She has written several blog posts and participates in patient-facing informational panels, with the goal of increasing public awareness and knowledge of pathology reports and laboratory testing. In her free time, she enjoys collecting rare and vintage medical books, reading historical fiction, karaoke and home gardening. TOP 10 PATHOLOGY QUESTIONS 1. How do I find and understand my pathology report? What should I pay attention to in my pathology report? 2. What type of staining should be done for NET tumors? 3. How does the tumor location play a role in what testing a pathologist might do? 4. What is tumor grade, why is it important, and how is that determined? How is grade different from stage? 5. What is ki67? How reliable is this? 6. What is mitosis or mitotic index? 7. What is differentiation and how do you decide this? Is it ever ambiguous? How are poorly differentiated tumors different from other tumors? 8. What do typical and atypical mean and when might we see this? 9. Can there be different grades within the same tumor or between multiple tumors? How do I understand a pathology report that showed mixed neuroendocrine neoplasms? 10. Should I get a second opinion with my pathology? If so, how is that done? Also, how long are pathology specimens typically stored? ADDITIONAL RESOURCES "Your Pathologist & Your Pathology Report" with Dr. Chang and Dr. Li Click here for another helpful resource on how to read your pathology report. DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES PART II: Intra-Arterial Techniques and Sequencing Download a Transcript of this Episode >>> ABOUT THIS EPISODE In this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures. MEET DR. OSMAN AHMED Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY, INCLUDING INTRA-ARTERIAL TECHNIQUES & SEQUENCING: What do patients need to know about bland embolization (TAE)? a. What are the possible side effects? b. How do the size of beads play a role? c. When is this recommended? d. Do you always do both sides of the liver? If so, what is the timing and why? e. What is the recovery like? What is post-embolization syndrome? What do patients need to know about chemoembolization (TACE)? a. What drug is used & does this go through the whole body? b. What is the recovery like? What are the possible side effects? What do patients need to know about radioembolization (TARE, SIRT, y90)? a. In the era of PRRT, is there a concern with using y90 or radioembolization? How is the approach and techniques used with radioembolization different than how it was done in the past? Is there a total lifetime limit of radiation? b. What is the recovery like? What are the possible side effects? Is there a limit to how much LDT one can do? Can they be repeated? How does one decide between the various types of liver-directed therapies? Is there a sequencing to treatments? Are there certain treatments that make you ineligible for other treatments? [PRRT, chemo, y90 etc] If someone has had surgery such as a Whipple or surgery or procedures involving the bile duct such as a stent in the bile duct or surgical removal of part of the bile duct, how does this weigh into the decision-making process for LDT? How do you determine if the treatment “worked?” What is the follow up like? What scan might you do and in what timing? What do you see as the future of liver-directed therapy in neuroendocrine cancer treatment? RESOURCES LISTEN Episode 38: NEN Treatments: Focus on Liver-Directed Therapies (Part I: Overview and Ablative Techniques Including Histotripsy) WATCH LACNETS Liver-Directed Therapy Videos DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

< Back to the upcoming events page Download the Transcript Here >>> Download the Presentation Slides Here >>> ABOUT Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. ABOUT LINDA GARDNER, MSN, RN, VA-BC LINDA (LINDY) GARDNER, MSN, RN, VA-BC Lead Nurse, Nuclear Medicine UCLA Health Lindy has over two decades of Interventional Radiology experience prior to transitioning over to Nuclear Medicine in March of 2017. She obtained her RN qualification in 1993 from John Moores University of Liverpool, (LJMU) United Kingdom, she is a graduate from the University Of Dundee, Scotland where she received her Bachelors, and Master’s of Science in Nursing. In her Nuclear Medicine role Lindy is the lead nurse for the Peptide Receptor Radionuclide Therapy (PRRT) program, from the expanded access program (EAP) through to the FDA approved commercial program. She has presented this program to a national and international audience; her skills are utilized as an expert liaison for institutions commencing the PRRT program, focusing on the patient experience, education, and therapy administration. Lindy is the nursing pillar lead for The International Center for Precision Oncology foundation (ICPO), with her focus on education, support and navigation for the NET patient journey. She is also the lead nurse for Radioligand Therapy (RLT) for prostate cancer within Theranostics at UCLA, covering both clinical application and research. Lindy is a member of the Association for Radiologic and Imaging Nursing (ARIN), and the Association for Vascular Access (AVA), holding her board certification in vascular access (VACC). She serves as a member of the Neuroendocrine Cancer Foundation Medical Advisory Committee and The Healing NET Scientific Advisory Committee. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

< Back to the upcoming events page MONTHLY Virtual NET Caregiver Support Group Meetings Typically the last Saturday of every month 8:00 - 10:00 AM Pacific 2025 Dates: Jan 18, 2025 Apr 26, 2025 Jul 19, 2025 Oct 18, 2025 Feb 15, 2025 May 31, 2025 Aug 23, 2025 Nov 22, 2025 Mar 22, 2025 Jun 28, 2025 Sep 27, 2025 Dec 20, 2025 We provide a safe space where NET Caregivers can come together virtually for support, connection and community. We encourage you to express your experiences, thoughts and feelings in this safe space. Unlike our weekly networking group, our Caregiver Support Group does not focus on exchanging information on medical resources. Instead, we focus on the unique experiences and concerns of caregivers and provide emotional support to those affected by NET. *OPEN TO NET CAREGIVERS ONLY. The zoom link is provided in the RSVP confirmation and will also be emailed to you prior to the support meeting. Questions? Need technical support? Email events@LACNETS.org . *Limited spots available. REGISTER THANKS TO OUR SUPPORTERS

< Back to the upcoming events page ABOUT Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. Download Presentation Slides >>> ABOUT MEGHAN LASZLO, MS, RD, CSO Registered Dietitian Board-Certified Specialist in Oncology Nutrition Meghan Laszlo MS, RD, CSO is an oncology dietitian at Cedars-Sinai in Los Angeles, California. For individuals outside of Cedars-Sinai, Meghan Laszlo sees patients through Nourish, a telehealth platform that accepts insurance (Aetna, BCBS, Cigna, United). Insurance for telehealth is available to those residing in Arizona, California, Colorado, Connecticut, Hawaii, Idaho, Indiana, Massachusetts, Michigan, New Hampshire, New Jersey, New York, Oklahoma, Oregon, Pennsylvania, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and Wyoming! Meghan Laszlo MS, RD, CSO Phone: 424-235-5026 RESOURCES T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Lu-177 DOTATATE + Olaparib in GEP-NETs << Back Lu-177-DOTATATE in Combination With Olaparib in Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) CLINICALTRIALS.GOV IDENTIFIER: NCT04086485 DRUG/TREATMENT: Lu-177 DOTATATE + OLAPARIB PHASE I / II STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) Dr. Del Rivero discusses Lu177-Dotatate + OLAPARIB DESCRIPTION: This phase 1-2 trial tests Lu-177-DOTATATE (Lutathera) in combination With olaparib (PARP inhibitor) in inoperable gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). The objective is to learn if people with certain neuroendocrine tumors can take a combination of 2 drugs, Lu-177 DOTATATE and Olaparib, without having severe side effects, and if this treatment makes the tumors shrink. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. PRINCIPAL INVESTIGATOR: Frank Lin, MD CONTACT: National Cancer Institute Joy Zou, RN EMAIL: joy.zou@nih.gov PHONE: 240-760-6153

225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC << Back A Phase 1a/b, Open-label, Dose-escalation Study of the Safety, Pharmacokinetics, and Initial Efficacy of 225Ac-ABD147 in Patients With Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma of the Lung Following Platinum-based Chemotherapy IDENTIFIER ( ClinicalTrials.gov ) : NCT06736418 DRUG/TREATMENT : 225Ac-ABD147 PHASE : 1A/B STATUS : Recruiting SPONSOR : A bdera Therapeutics Inc. DLL-3-RLT Presentation Slides .pdf Download PDF • 863KB DESCRIPTION: This is an open-label, Phase 1a/1b, first-in-human study testing a new targeted treatment called 225Ac-ABD147 for people with locally advanced or metastatic small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung. All participants must have previously received platinum-based chemotherapy. What is 225Ac-ABD147? 225Ac-ABD147 is a DLL3-targeting antibody fragment, a small, engineered piece of an antibody that targets cancer cells with a marker called delta-like ligand 3 (DLL3) . It is attached to a special linker-chelator that holds a radioactive particle ( Actinium-225 ) so that a precise dose of radiation can be delivered directly to DLL3-positive cancer cells. The study has two parts: Phase 1a and Phase 1b . Phase 1a: Safety, Dosing & Early Signals Phase 1a is designed to understand: Safety and side effects How the drug moves through the body (PK and biodistribution) Early signs of effectiveness The safest and most appropriate dose levels A small group of participants will also receive an experimental imaging agent, 111In-ABD147 , to help researchers see how the treatment travels and where it binds in the body. Phase 1b: Expanded Testing at Selected Doses Phase 1b uses the dose levels identified in Phase 1a to further evaluate: Safety How well the treatment works for SCLC and LCNEC This phase helps researchers better understand the potential benefit of 225Ac-ABD147 in these cancers. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT Abdera Therapeutics Inc. EMAIL: AbderaClinicalTrials@abderatx.com PHONE: 1 650-434-4093 This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information.

DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers << Back DAREON™ 5: DLL-3 BiTE for Neuroendocrine Cancers IDENTIFIER ( ClinicalTrials.gov ) : NCT05882058 DRUG/TREATMENT : BI 764532 PHASE : 2 STATUS : Recruiting SPONSOR : Boehringer Ingelheim DESCRIPTION: Boehringer Ingelheim is sponsoring DAREON™ -5, a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT : Boehringer Ingelheim EMAIL: clintriage.rdg@boehringer-ingelheim.com PHONE: 1-800-243-0127 Visit this patient-friendly website for the DAREON-5 clinical trial program for more information>>>